BioWorld

Feb. 28, 2008

FDA Pledges Renewed Focus to Boost Post-Market Safety

More than 100 years after the creation of the FDA, the agency said it now will apply the same standards it uses in its premarket drug reviews to manage its post-marketing safety process. (BioWorld Today) Read More

Regeneron Gets FDA's OK for Arcalyst in CAPS

New Connections of Clotting to Inflammation in Sepsis, MS

NewCo News: Profectus Seeks a Bio Niche Hitting HIV from all Angles

Biogen, Elan Nicked on Reports of Tysabri-Linked Liver Injuries

RegeneRx Secures $5M for Wound Healing Trials

Receptor Logic Finds Partner to Develop T-Cell Mimics

Other News To Note

Earnings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 27, 2026.

Detecting the invisible: minimal residual disease at AACR 2026

BioWorld Science

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...

Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

BioWorld Science

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...